Literature DB >> 27190185

Genital Anaerobic Bacterial Overgrowth and the PrePex Male Circumcision Device, Rakai, Uganda.

Cindy M Liu1, Jessica L Prodger2, Aaron A R Tobian3, David Serwadda4, Ronald M Galiwango4, Fred Nalugoda4, Nehemiah Kighoma4, Joshua Mwinike4, Margaret Anyokorit4, Lance B Price5, Maria J Wawer6, Godfrey Kigozi4, Ronald H Gray6.   

Abstract

The PrePex circumcision device causes ischemic necrosis of the foreskin, raising concerns of anaerobic overgrowth. We compared the subpreputial microbiome of 2 men 7 days after PrePex device placement to that of 145 uncircumcised men in Rakai, Uganda, using 16S ribosomal (rRNA) RNA gene-based quantitative polymerase chain reaction analysis and sequencing. PrePex users had higher absolute abundance of all bacteria than uncircumcised men (P = .001), largely due to increased numbers of the following anaerobes: Porphyromonas (5.2 × 10(7) 16S rRNA gene copies/swab in the PrePex group and 1.1 × 10(6) 16S rRNA gene copies/swab in uncircumcised men; P = .002), Peptoniphilus (1.0 × 10(7) and 1.8 × 10(6) 16S rRNA gene copies/swab, respectively; P < .05), Anaerococcus (1.0 × 10(7) and 1.1 × 10(6) 16S rRNA gene copies/swab, respectively; P < .001), and Campylobacter ureolyticus (1.7 × 10(5) and 1.6 × 10(7)16S rRNA gene copies/swab, respectively; P < .001). The PrePex-associated increase in anaerobes may account for unpleasant odor and a possible heightened risk of tetanus.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  PrePex device; Uganda; anaerobes; male circumcision; penile microbiota; tetanus

Mesh:

Substances:

Year:  2016        PMID: 27190185      PMCID: PMC4957438          DOI: 10.1093/infdis/jiw182

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Odor mortis.

Authors:  Arpad A Vass
Journal:  Forensic Sci Int       Date:  2012-06-22       Impact factor: 2.395

2.  Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial.

Authors:  Ronald H Gray; Godfrey Kigozi; David Serwadda; Frederick Makumbi; Stephen Watya; Fred Nalugoda; Noah Kiwanuka; Lawrence H Moulton; Mohammad A Chaudhary; Michael Z Chen; Nelson K Sewankambo; Fred Wabwire-Mangen; Melanie C Bacon; Carolyn F M Williams; Pius Opendi; Steven J Reynolds; Oliver Laeyendecker; Thomas C Quinn; Maria J Wawer
Journal:  Lancet       Date:  2007-02-24       Impact factor: 79.321

3.  Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.

Authors:  Robert C Bailey; Stephen Moses; Corette B Parker; Kawango Agot; Ian Maclean; John N Krieger; Carolyn F M Williams; Richard T Campbell; Jeckoniah O Ndinya-Achola
Journal:  Lancet       Date:  2007-02-24       Impact factor: 79.321

4.  Male circumcision for the prevention of HSV-2 and HPV infections and syphilis.

Authors:  Aaron A R Tobian; David Serwadda; Thomas C Quinn; Godfrey Kigozi; Patti E Gravitt; Oliver Laeyendecker; Blake Charvat; Victor Ssempijja; Melissa Riedesel; Amy E Oliver; Rebecca G Nowak; Lawrence H Moulton; Michael Z Chen; Steven J Reynolds; Maria J Wawer; Ronald H Gray
Journal:  N Engl J Med       Date:  2009-03-26       Impact factor: 91.245

5.  Notes from the Field: Tetanus Cases After Voluntary Medical Male Circumcision for HIV Prevention--Eastern and Southern Africa, 2012-2015.

Authors:  Jonathan M Grund; Carlos Toledo; Stephanie M Davis; Renee Ridzon; Edna Moturi; Heather Scobie; Boubker Naouri; Jason B Reed; Emmanuel Njeuhmeli; Anne G Thomas; Francis Ndwiga Benson; Martin W Sirengo; Leon Ngeruka Muyenzi; Gissenge J I Lija; John H Rogers; Salli Mwanasalli; Elijah Odoyo-June; Nafuna Wamai; Geoffrey Kabuye; James Exnobert Zulu; Jane Ruth Aceng; Naomi Bock
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-01-22       Impact factor: 17.586

Review 6.  Voluntary medical male circumcision in resource-constrained settings.

Authors:  Aaron A R Tobian; Tigistu Adamu; Jason B Reed; Valerian Kiggundu; Youseph Yazdi; Emmanuel Njeuhmeli
Journal:  Nat Rev Urol       Date:  2015-11-03       Impact factor: 14.432

7.  Reclassification of Bacteroides ureolyticus as Campylobacter ureolyticus comb. nov., and emended description of the genus Campylobacter.

Authors:  P Vandamme; L Debruyne; E De Brandt; E Falsen
Journal:  Int J Syst Evol Microbiol       Date:  2009-10-02       Impact factor: 2.747

8.  Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial.

Authors:  Bertran Auvert; Dirk Taljaard; Emmanuel Lagarde; Joëlle Sobngwi-Tambekou; Rémi Sitta; Adrian Puren
Journal:  PLoS Med       Date:  2005-10-25       Impact factor: 11.069

9.  Adverse events profile of PrePex a non-surgical device for adult male circumcision in a Ugandan urban setting.

Authors:  Moses Galukande; Kevin Duffy; Jean Paul Bitega; Sam Rackara; Denis Sekavuga Bbaale; Florence Nakaggwa; Teddy Nagaddya; Nick Wooding; Monica Dea; Alex Coutinho
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

10.  The safety and acceptance of the PrePex device for non-surgical adult male circumcision in Rakai, Uganda. A non-randomized observational study.

Authors:  Godfrey Kigozi; Richard Musoke; Stephen Watya; Nehemia Kighoma; James Nkale; Mary Nakafeero; Dan Namuguzi; David Serwada; Fred Nalugoda; Nelson Sewankambo; Maria Joan Wawer; Ronald Henry Gray
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

View more
  2 in total

1.  Ockham's Razor and the PrePex Male Circumcision Device.

Authors:  Cindy M Liu; Aaron A R Tobian; Ronald H Gray
Journal:  J Infect Dis       Date:  2016-07-11       Impact factor: 5.226

2.  The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection.

Authors:  Harris Onywera; Anna-Lise Williamson; Luca Cozzuto; Sarah Bonnin; Zizipho Z A Mbulawa; David Coetzee; Julia Ponomarenko; Tracy L Meiring
Journal:  BMC Microbiol       Date:  2020-04-06       Impact factor: 3.605

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.